J
James R. Rigas
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 63
Citations - 4568
James R. Rigas is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 25, co-authored 60 publications receiving 4371 citations. Previous affiliations of James R. Rigas include Eastern Cooperative Oncology Group & University of Toronto.
Papers
More filters
Journal ArticleDOI
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Timothy Winton,Robert B. Livingston,David H. Johnson,James R. Rigas,Michael R. Johnston,Charles Butts,Yvon Cormier,Glenwood D. Goss,Richard Inculet,Eric Vallières,Willard A Fry,Drew Bethune,Joseph Ayoub,Keyue Ding,Lesley Seymour,Barbara Graham,Ming-Sound Tsao,David R. Gandara,Kenneth A. Kesler,Todd L. Demmy,Frances A. Shepherd +20 more
TL;DR: Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.
Journal ArticleDOI
Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients.
Nael Martini,Mark G. Kris,Betty J. Flehinger,Richard J. Gralla,Manjit S. Bains,Michael E. Burt,Robert T. Heelan,Patricia M. McCormack,Katherine M.W. Pisters,James R. Rigas,Valerie W. Rusch,Robert J. Ginsberg +11 more
TL;DR: It is demonstrated that preoperative chemotherapy with MVP produces high response rates in stage IIIa (N2) disease, high complete resection rates occur after response to chemotherapy, and survival is longest in patients who have acomplete resection after major response to chemo.
Journal ArticleDOI
Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer
Ming-Sound Tsao,Sarit Aviel-Ronen,Keyue Ding,Davina Lau,Ni Liu,Akira Sakurada,Marlo Whitehead,Chang-Qi Zhu,Robert B. Livingston,David H. Johnson,James R. Rigas,Lesley Seymour,Timothy Winton,Frances A. Shepherd +13 more
TL;DR: In this paper, the prognostic and predictive value of p53 gene/protein aberrations using tumor samples from JBR.10, a North American phase III intergroup trial that randomly assigned 482 patients with completely resected stage IB and II non-small-cell lung cancer (NSCLC) to receive four cycles of adjuvant cisplatin plus vinorelbine or observation alone.
Journal ArticleDOI
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
Prudence A. Francis,James R. Rigas,James R. Rigas,Mark G. Kris,Katherine M.W. Pisters,John P. Orazem,Karen J. Woolley,Robert T. Heelan +7 more
TL;DR: At this dose and schedule, docetaxel demonstrates significant antitumor activity in patients with advanced NSCLC.
Journal ArticleDOI
Adjuvant Vinorelbine and Cisplatin in Elderly Patients: National Cancer Institute of Canada and Intergroup Study JBR.10
C. Pepe,Baktiar Hasan,Timothy Winton,Lesley Seymour,Barbara Graham,Robert B. Livingston,David H. Johnson,James R. Rigas,Keyue Ding,Frances A. Shepherd +9 more
TL;DR: Despite elderly patients' receiving less chemotherapy, adjuvant vinorelbine and cisplatin improves survival in patients older than 65 years with acceptable toxicity, and adjuvant chemotherapy should not be withheld from elderly patients.